Novartis impresses with 2005 product pipeline
January 12, 2005 - One drug that is expected to make waves in the long term is transplant drug FTY720. The treatment works by a unique mechanism of action, directing T-cells away from the graft.
Despite its long-term importance, in the short and medium term only modest sales are expected due to the need to build clinical trial data and to the conservative nature of transplantation physicians. Transplantation is seen as a good business, that requires little marketing and relative lack of competition for effective treatments
There is potential for FTY720 in multiple sclerosis (currently in Phase II, data expected January 20). However, the company acknowledged that it would likely be five years before FTY720 has an impact on Novartis’ sales. Phase III data in 2005, was expected with a 2006 launch anticipated.
http://www.drugresearcher.com/news/news ... esses-with